Literature DB >> 11523050

Absence of tpr-met and expression of c-met in human gastric mucosa and carcinoma.

D A Heideman1, P J Snijders, E Bloemena, C J Meijer, G J Offerhaus, S G Meuwissen, W R Gerritsen, M E Craanen.   

Abstract

The c-met proto-oncogene, encoding the hepatocyte growth factor receptor, can be activated by various mechanisms. These include, among others, gene amplification with concomitant overexpression and the tpr-met oncogenic rearrangement. In the case of gastric cancer, contradictory results on the presence of the tpr-met oncogenic rearrangement have been published. The current study aimed therefore to assess the prevalence of tpr-met expression in Caucasian gastric adenocarcinomas, to evaluate the importance of this oncogene in their carcinogenesis. In addition, the level of c-met expression was determined, to evaluate the role of this alternative mode of activation of the proto-oncogene. A series of Caucasian gastric adenocarcinomas (n=43) and normal gastric mucosal samples (n=14) was analysed for tpr-met and c-met expression. Expression of tpr-met mRNA in the samples was performed by two reverse transcriptase polymerase chain reaction (RT-PCR) assays, with excellent correlation. The specificity of both methods was confirmed by direct sequencing of the PCR products of the MNNG-HOS cell line, which is known to contain the rearrangement. The level of c-met expression was assessed using semi-quantitative RT-PCR assays and immunohistochemistry (IHC). None of the normal gastric mucosal or gastric adenocarcinoma samples expressed tpr-met mRNA, as determined by both RT-PCR assays. Seventy per cent of the adenocarcinomas showed overexpression of c-met, according to elevated c-met mRNA levels, compared with the expression level of normal gastric mucosa. A significant correlation was found between the level of c-met mRNA and protein expression. In conclusion, these results strongly suggest that tpr-met activation does not play a role in Caucasian gastric carcinogenesis, while overexpression of the c-met gene occurs in the majority of Caucasian gastric adenocarcinomas. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523050     DOI: 10.1002/path.934

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  9 in total

1.  Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

Authors:  Alex A Adjei; Brian Schwartz; Edward Garmey
Journal:  Oncologist       Date:  2011-05-31

2.  Quantitative proteomics discloses MET expression in mitochondria as a direct target of MET kinase inhibitor in cancer cells.

Authors:  Tiannan Guo; Yi Zhu; Chee Sian Gan; Sze Sing Lee; Jiang Zhu; Haixia Wang; Xin Li; James Christensen; Shiang Huang; Oi Lian Kon; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2010-08-16       Impact factor: 5.911

3.  Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome.

Authors:  Tiannan Guo; Sze Sing Lee; Wai Har Ng; Yi Zhu; Chee Sian Gan; Jiang Zhu; Haixia Wang; Shiang Huang; Siu Kwan Sze; Oi Lian Kon
Journal:  Cell Mol Life Sci       Date:  2010-10-16       Impact factor: 9.261

Review 4.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

Review 5.  Clinical significance of MET in gastric cancer.

Authors:  Mikito Inokuchi; Sho Otsuki; Yoshitaka Fujimori; Yuya Sato; Masatoshi Nakagawa; Kazuyuki Kojima
Journal:  World J Gastrointest Oncol       Date:  2015-11-15

6.  The clinicopathologic association of c-MET overexpression in Iranian gastric carcinomas; an immunohistochemical study of tissue microarrays.

Authors:  Kambiz Sotoudeh; Forough Hashemi; Zahra Madjd; Alireza Sadeghipour; Saadat Molanaei; Elham Kalantary
Journal:  Diagn Pathol       Date:  2012-05-28       Impact factor: 2.644

7.  Activating MET kinase rearrangements in melanoma and Spitz tumours.

Authors:  Iwei Yeh; Thomas Botton; Eric Talevich; A Hunter Shain; Alyssa J Sparatta; Arnaud de la Fouchardiere; Thaddeus W Mully; Jeffrey P North; Maria C Garrido; Alexander Gagnon; Swapna S Vemula; Timothy H McCalmont; Philip E LeBoit; Boris C Bastian
Journal:  Nat Commun       Date:  2015-05-27       Impact factor: 14.919

8.  P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy.

Authors:  Rabin Said; David S Hong; Carla L Warneke; J Jack Lee; Jennifer J Wheler; Filip Janku; Aung Naing; Gerald S Falchook; Siqing Fu; Sarina Piha-Paul; Apostolia M Tsimberidou; Razelle Kurzrock
Journal:  Oncotarget       Date:  2013-05

9.  Clinicopathological Significance and Diagnostic Accuracy of c-MET Expression by Immunohistochemistry in Gastric Cancer: A Meta-Analysis.

Authors:  Jung-Soo Pyo; Guhyun Kang; Hyunjin Cho
Journal:  J Gastric Cancer       Date:  2016-09-30       Impact factor: 3.720

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.